Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review

BACKGROUND: Renal cell carcinoma (RCC) is a common malignancy with approximately 30% of cases diagnosed at the advanced or metastatic stage. While single-agent vascular endothelial growth factor-targeted therapy has been a mainstay of treatment, data from multiple phase III trials assessing first-li...

Descripción completa

Detalles Bibliográficos
Autores principales: Lalani, Aly-Khan A., Heng, Daniel Y. C., Basappa, Naveen S., Wood, Lori, Iqbal, Nayyer, McLeod, Deanna, Soulières, Denis, Kollmannsberger, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244935/
https://www.ncbi.nlm.nih.gov/pubmed/35782749
http://dx.doi.org/10.1177/17588359221108685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244935/
https://www.ncbi.nlm.nih.gov/pubmed/35782749
http://dx.doi.org/10.1177/17588359221108685

Ejemplares similares